Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
NCT ID: NCT02301962
Last Updated: 2019-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
58 participants
INTERVENTIONAL
2015-07-28
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All adverse events occurring from signing of informed consent form until 8 weeks after last dose of panitumumab will be recorded. All Serious Adverse Events (SAE) considered related to panitumumab by the investigator or the sponsor will be followed until the event resolves, or is considered stable or until the subject is lost to follow-up or withdraws consent.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Panitumumab arm
Subjects will receive panitumumab 6 mg/kg intravenously as monotherapy every 14 days until disease progression, intolerability, withdrawal of consent, or death.
Panitumumab
Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Panitumumab
Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female \>=18 years of age.
* Histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum.
Metastatic disease.
* Wild-type KRAS (without mutation in exon 2 \[codons 12 and 13\], exon 3 \[codons 59 and 61\], and exon 4 \[codons 117 and 146\]) and wild-type NRAS (without mutation in exon 2 \[codons 12 and 13\], exon 3 \[codons 59 and 61\], and exon 4 \[codons 117 and 146\]) tumor status.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
* Measurable or non-measurable disease per RECIST Version 1.1.
* Must have failed after fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens for metastatic disease. Failure is defined as either disease progression (clinical or radiological) or intolerance to the regimen. Metastatic relapse within 6 months after completing adjuvant chemotherapy (with either an irinotecan or oxaliplatin containing regimen) will also be considered as treatment failure of a prior regimen for metastatic disease. Laboratory: Adequate baseline organ function defined by (\<=7 days prior to first dose of study treatment).
* Hematologic function, as follows: Absolute neutrophil count (ANC) \>=1.5 x 10\^9/Liter (L), Platelet count \>=75 x 10\^9/L, Hemoglobin \>=8.0 gram/deciliter (g/dL).
* Renal function, as follows: Creatinine \<=1.5 x upper limit of normal (ULN).
* Hepatic function, as follows: Aspartate aminotransferase (AST) \<=3 x ULN, Alanine aminotransferase (ALT) \<=3 x ULN, Total Bilirubin \<=1.5 x ULN.
* Metabolic function, as follows: Serum Magnesium within normal limits. Serum Calcium within normal limits. Serum Potassium within normal limits.
* All prior treatment related toxicities common terminology criteria for adverse events (CTCAE) version 4.03 \<=Grade 1 at the time of enrollment.
* Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use adequate contraception, during the study and for 2 months following the last dose of study treatment. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use adequate contraception, from time of signing informed consent until 5 months after the last dose of study treatment.
Exclusion Criteria
* History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for \>=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to panitumumab or excipients that contraindicates their participation.
* Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (e.g., panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib).
* Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy \<=30 days before first dose of study treatment or not recovered from any acute toxicity.
* Other investigational procedure \<=30 days before study entry.
* History of interstitial lung disease (ILD) e.g., interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography.
* Subject previously enrolled to this study.
* History of keratitis, ulcerative keratitis or severe dry eye.
* Major surgery (e.g., requiring general anesthesia) \<=30 days before first dose of study treatment. Subjects must have recovered from any surgery related toxicities.
* Minor surgical procedure (e.g., open biopsy) \<=7 days before first dose of study treatment, or not yet recovered from prior minor surgery Note: uncomplicated placement of vascular access device, fine needle aspiration, thoracocentesis or paracentesis \>=3 days prior to first dose of study treatment is acceptable.
* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) \<=6 months prior to enrolment.
* History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with the study participation or investigational product administration, compliance with the study procedures or may interfere with the interpretation of the results.
* Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event \<=30 days before first dose of study treatment. If on anticoagulation, subject must be on stable therapeutic dose prior to first dose of study treatment.
* Subject who is pregnant or breast feeding, or planning to become pregnant during treatment and within 2 months after the discontinuation of study treatment.
* Known positive test(s) for human immunodeficiency virus infection (testing is not required in the absence of clinical suspicion).
* Active infection requiring systemic treatment or any uncontrolled infection \<=14 days prior to first dose of study treatment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).
* Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures or is unwilling or unable to comply with study requirements.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Dr. Reddy's Laboratories Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Lalit Lakhwani, MD
Role: STUDY_DIRECTOR
Dr. Reddys Laboratories Limited
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DRL Investigational Site
Vijayawada, Andhra Pradesh, India
DRL Investigational Site
Mumbai, Maharashtra, India
DRL Investigational Site
Nagpur, Maharashtra, India
DRL Investigational Site
Nashik, Maharashtra, India
DRL Investigational Site
Nashik, Maharashtra, India
DRL Investigational Site
Ludhiana, Punjab, India
DRL Investigational Site
Jaipur, Rajasthan, India
DRL Investigational Site
Madurai, Tamil Nadu, India
DRL Investigational Site
Hyderabad, Telangana, India
DRL Investigational Site
Kolkata, West Bengal, India
DRL Investigational Site
New Delhi, , India
DRL Investigational Site
New Delhi, , India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Sachin Joshi
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DRL-INDG02-PAN/2018
Identifier Type: -
Identifier Source: org_study_id